107 Results
Sort By:
Published on February 16, 2023
Natera announced today that it received written confirmation from the Centers for Medicare & Medicaid Services (CMS) that its Signatera molecular residual disease (MRD) test will be reimbursed for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer. The coverage is available across all subtypes including…
Published on November 29, 2022
HALO Diagnostics and Ikonopedia have announced a genetic testing partnership to improve breast cancer detection and outcomes. Under the deal, Ikonopedia’s proprietary mammography software will be used for “one-click” radiology reporting and follow-up tracking, when it is integrated with HALO’s genetic lab and precision diagnostic software services. The two companies…
Published on November 16, 2022
Scientists at Albert Einstein College of Medicine have developed a new anticancer strategy that they suggest could bolster the effectiveness of immune-checkpoint therapy. The team said their findings also point to a mechanism that may explain why the latest anti-TIGIT treatments may be failing in the clinic. Rather than rally…
Published on October 28, 2022
Medical genetics company Invitae announced on Thursday that it has inked a collaboration with pharma heavyweight AstraZeneca to leverage Invitae’s Ciitizen genomic and health history data in a retrospective and prospective study of patients diagnosed with the rare bile duct cancer cholangiocarcinoma. The patient-consented data for the study will come…
Published on August 24, 2022
Early stage cervical cancer rates fell by an annual 1.6%, but cases of advanced disease have increased by nearly 1.5% in the U.S. every year for the last couple of decades, a new study shows. The steepest rise in new cases of advanced womb (cervical) cancer in the U.S. is…
Published on August 8, 2022
Men’s greater susceptibility to cancer may be due to underlying biological sex differences rather than behavioral factors, such as smoking, alcohol use, and diet, according to results from a recent study published in Cancer. Men have a higher risk of cancer than women at most shared anatomic sites. Such male…
Published on June 7, 2022
All 14 patients who received GlaxoSmithKline’s (GSK’s) immunotherapy Jemperli (dostarlimab) for mismatch repair-deficient (MMRd) locally advanced rectal cancer had a complete response without needing chemotherapy or surgery. Jemperli is an anti-PD-1 monoclonal antibody. The latest stunning findings from this trial were presented at the 2022 ASCO Annual Meeting. Earlier results,…
Published on May 5, 2022
High BMI during childhood and puberty has been linked to higher risk of cancer in men later in life, according to a new study led by Jimmy Celind, researcher at Sahlgrenska Academy’s Institute of Medicine, Sweden. “Overweight in childhood followed by normal weight in young adulthood thus resulted in a…
Published on January 5, 2022
When his wife retrieved the Christmas lights from their garage in mid December, Foghorn Therapeutics President and CEO Adrian Gottschalk recalled, the decorations she unpacked presented an apt analogy for explaining the science behind his company, a developer of precision therapies. Just as the string of lights was tangled up…
Published on November 16, 2021
Research from Icahn School of Medicine at Mount Sinai shows that age of cancer onset is a strong differentiator between individuals in terms of molecular features. The research team found that immune response to cancer tended to differ in people aged 50 or younger compared to older individuals and that…
Published on March 15, 2021
High tumor mutation burden can predict improved response to immune checkpoint therapy for cancers such as melanoma, lung and bladder cancer, but is less useful at predicting treatment response for other solid tumors, show study results. The research team, led by scientists from the University of Texas MD Anderson Cancer…
Published on February 1, 2021
Finnish investigators have recently identified a protein trafficking receptor, usually studied in neurons, that plays a key role in breast cancer metastasis. The scientists at the University of Turku Bioscience Center observed that the Sortilin-related receptor (SorLA) functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor…
Published on November 3, 2020
Applying a machine learning technique using algorithms that learn transcriptome information from artificial organoids derived from actual patients instead of animal models, researchers from the Pohang University of Science and Technology (POSTECH) in South Korea say they have successfully increased the accuracy of anti-cancer drug response predictions. The team, led…
Published on November 3, 2020
In a finding that bolsters the field of personalized medicine, a new large-scale study from the Mayo Clinic reports that one in eight cancer patients they followed had an inherited mutation that increases their risk of developing a malignancy. Further, the study showed that more than half of all patients…
Published on October 22, 2020
Preliminary findings from a trial involving cancer patients taking immune checkpoint treatment with PD-L1 inhibitors reveal that simultaneous treatment with angiotensin receptor II blockers (ARBs) improve patients’ responses. The results were presented by Julius Strauss, co-director of the clinical trials group at the Laboratory of Tumor Immunology and Biology, at…